A minor cannabinoid with great therapeutic benefits, this is how we could describe cannabigiberol (CBG). Cannabinoids are plant molecules that influence its therapeutic property.
It is considered minor since it is usually found in small quantities, that is why, currently, geneticists experiment to increase their percentage to more than 1%.
CBG is considered a precursor to delta 9 tetrahydrocannabinol (THC) and cannabidiol (CBD). It has also been found to work in a variety of fields, seeing important medical promise as an anti-inflammatory, antibacterial and in reducing tumor growth.
Some studies on the subject are:
– For cancer there are two important studies. In the first, scientists discovered that this cannabinoid could block the growth of cancer tumors. The test was performed on chemical agents that induced colon cancer that were inhibited in their growth by CBG.
– CBG as antibacterial agents. This was the conclusion of a 2017 study, in which this cannabinoid was effective as an antibacterial agent against Staphylococcus aureus bacteria.
– Studies in mice have proven its anti-inflammatory effect. CBG has been shown to be an anti-inflammatory agent against bladder disease.
– Another major 2015 report reports CBG’s ability to protect neurons in Huntington’s disease, a neurodegenerative disease.
Some companies that work with hemp have seen a new opportunity in this cannabinoid. While the learning curve for cannabidiol (CBD) is only just beginning to be digested in the population, the development of new genetics high in CBG could have a field of development in the next two years.